Back to Search
Start Over
Circulating levels of VEGFR-1 and VEGFR-2 in patients with metastatic melanoma treated with chemoimmunotherapy alone or combined with bevacizumab
- Source :
- Melanoma Research. 21:431-437
- Publication Year :
- 2011
- Publisher :
- Ovid Technologies (Wolters Kluwer Health), 2011.
-
Abstract
- There are no identified biomarkers that could predict response to antiangiogenic or traditional chemoimmunotherapy in metastatic melanoma. We hypothesized that soluble angiogenic factor receptors might help us to identify patients responsive to treatment. A series of 48 patients with stage IV melanoma participating in two phase II clinical trials were included. The trials included treatment with carboplatin, vinorelbine, and subcutaneous interleukin-2 (n=22) or treatment with bevacizumab, dacarbazine, and low-dose interferon-α2a (n=26).Serum samples were prospectively collected and soluble vascular endothelial growth factor receptor 1 (s-VEGFR-1) and 2 (s-VEGFR-2) were measured before starting the trial treatment and during response evaluation.There was a trend toward longer overall survival among patients with higher-than-median serum VEGFR-1 levels (21.3 months) compared with 12.3 months in patients with low pretreatment s-VEGFR-1 levels (P=0.146). Pretreatment s-VEGFR-2 levels did not correlate to survival. Serum VEGFR-2 levels decreased during therapy in 44% of the patients and increased in 56% of the patients. VEGFR-2 increased in 78% (14 of 18) of the patients who progressed during therapy (P=0.017). VEGFR-2 decrease was associated with clinical benefit in 65% of the patients (11 of 17) and with progression in only four patients (P=0.016).High pretreatment levels of s-VEGFR-1 are associated with improved prognosis among patients with metastatic melanoma independently on therapy, whereas increased VEGFR-2 levels during therapy are associated with disease progression. These markers might be useful in selecting patients responsive to antiangiogenic therapy.
- Subjects :
- Adult
Male
Cancer Research
Skin Neoplasms
Bevacizumab
Metastatic melanoma
VEGF receptors
Dermatology
Antibodies, Monoclonal, Humanized
Text mining
Chemoimmunotherapy
Antineoplastic Combined Chemotherapy Protocols
Biomarkers, Tumor
medicine
Humans
In patient
Prospective Studies
Neoplasm Metastasis
Receptor
Melanoma
Aged
Vascular Endothelial Growth Factor Receptor-1
biology
business.industry
Middle Aged
Vascular Endothelial Growth Factor Receptor-2
Oncology
Cancer research
biology.protein
Female
business
Stage iv
Biomarkers
medicine.drug
Subjects
Details
- ISSN :
- 09608931
- Volume :
- 21
- Database :
- OpenAIRE
- Journal :
- Melanoma Research
- Accession number :
- edsair.doi.dedup.....221dca366c7881d838ea56f046f5db0c